Navigation Links
GENFIT: Strong U.S. Exposure for Its Biomarker Activity
Date:1/6/2011

diagnostic solutions for these same diseases at very early stages. In this context, our newsflow in the biomarker area will be particularly active this year."

About GENFIT:GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...).  GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI-AVENTIS, SERVIER,...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Items in this press release may contain forward-looking statements involving risks and uncertainties.  The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus.  This press release has been prepared in both French and English languages.  In the event of any differences between the two texts, the French language version shall supersede.Contacts:GENFITJean-Francois Mouney – CEO & Chairman of the Management Board+33 (0)3 2016 4000MILESTONES – Press RelationsBruno Arabian+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 –

SOURCE GENFIT
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Medicine Announces Strong Second Quarter 2008 Results
2. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
3. Dry adhesive based on carbon nanotubes gets stronger, with directional gripping ability
4. Senetek Affirms Strong Financial Position
5. Strong elasticity size effects in ZnO nanowires
6. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
7. Cephalon Reports Another Strong Quarter
8. Shires New Product Portfolio Delivers Strong Quarterly Performance
9. OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services
10. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
11. ACORN CRO Continues Growth in Strong Third Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Oct. 21 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... nationwide and internationally, is pleased to announce that Chairman, CEO ... Operations, will appear for one hour live on "Go Rogue ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... financial results on Wednesday, October 27, 2010, after the market ... call at 5:00 p.m. ET, which will be open to ... the company will review the financial results and discuss other ...
... and NEW YORK, Oct. 20 ACCESS ... ACCP ), a biopharmaceutical company leveraging its proprietary drug-delivery ... supportive care and diabetes, announced it has submitted additional ... formulations of many global top-100 injectable drugs, as a ...
Cached Biology Technology:Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network 2Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3
(Date:7/9/2014)... of Adlie penguins shows that the population is ... than previously estimated. Adlie penguins have long been ... understand the effects of climate change and fishing ... satellite imagery, researchers from Stony Brook University and ... that permits regular monitoring of Adlie penguins across ...
(Date:7/9/2014)... an economy driven by methane, the primary component of natural ... production boom. It has poised the country as a top ... over just how climate-friendly it is, according to an article ... news magazine of the American Chemical Society. , In the ... when burned as a fuel to produce electricity, methane emits ...
(Date:7/9/2014)... at the NIH,s National Center for Advancing ... treat sickle cell disease has been acquired ... candidate, Aes-103, is the first specifically developed ... sickle cell disease. Baxter now will advance ... approval and commercialization. , Sickle cell disease ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... 5, 2008 Scientists report online this week in ... of specialized gut immune cells to a gene associated ... inflammatory bowel disorder. The link to immune cells ... St. Louis because they and others believe Crohn,s disease ...
... found the key to engineering plants capable of thriving ... report published online on October 2nd in Current ... that is generally plentiful in the earth,s crustcauses particular ... where acidic environments turn the metal into a form ...
... the power of 21st century computing to confirm an idea ... cycles evolve faster. Their findings appear in the October 3rd ... consequence for the understanding of evolution made possible by the ... said senior author Michael Donoghue , the G. Evelyn ...
Cached Biology News:Form of Crohn's disease traced to disabled gut cells 2How to build crops that can beat aluminum's toxic effects 2Reproducing early and often is the key to rapid evolution in plants 2
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Biology Products: